We assessed the virulence and anti-trypanosomal drug sensitivity patterns of Trypanosoma 19 brucei rhodesiense (Tbr) isolates in the Kenya Agricultural and Livestock Research 20 Organization-Biotechnology Research Institute (KALRO-BioRI) cryobank. Specifically, the 21 study focused on Tbr clones originally isolated from the western Kenya/eastern Uganda focus of 22 human African Trypanosomiasis (HAT). Twelve (12) Tbr clones were assessed for virulence 23 using groups(n=10) of Swiss White Mice monitored for 60 days post infection (dpi). Based on 24 survival time, four classes of virulence were identified: (a) very-acute: 0-15, (b) acute: 16-30, (c) 25 sub-acute: 31-45 and (d) chronic: 46-60 dpi. Other virulence biomarkers identified included: pre-26 patent period (pp), parasitaemia progression, packed cell volume (PCV) and body weight 2 27
Introduction 43
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a vector-borne 44 parasitic disease. It is caused by infection of humans with protozoan parasites belonging to the 45 genus Trypanosoma. HAT is caused by two species of trypanosomes, namely Trypanosoma 46 brucei gambiense and Trypanosoma brucei rhodesiense [1] .They are transmitted to humans by 47 tsetse fly (Glossina genus) [2] . Trypanosoma brucei gambiense is found in countries in West and 48 Central Africa and causes a chronic infection [3] . A person can be infected for months or even 49 years without major signs or symptoms of the disease [4] . When more evident symptoms 50 emerge, the patient is often already in an advanced disease stage where the central nervous 51 system is affected. Trypanosoma brucei rhodesiense is found in countries in eastern and southern 52 Africa and causes an acute infection Symptoms manifest within 2-4 weeks of infective bite [3] .
3 53 HAT develops in two stages namely, early (hemolymphatic) and late (meningo-encephalitic) 54 stage. In the early stage of the disease, parasites proliferate in the blood and lymphatic system 55 while in the late stage, parasites penetrate the blood brain barrier (BBB) and persist and 56 proliferate in the central nervous system (CNS), causing an encephalitic reaction that leads to 57 death if untreated or inadequately treated [5] . For first stage infections, there are no specific 58 clinical signs and symptoms in both forms of the disease; fever, headache and loss of appetite are 59 common [1] as well anemia in the monkey model [6] . With T.b. rhodesiense infections, first 60 signs and symptoms are observed a few weeks after infection; [1] . However, a mild form of 61 chronic T. b. rhodesiense infections with incubation times of several months has been reported in 62 Zambia [7] . The acute and the chronic HAT infections caused by T. b. rhodesiense in different 63 foci differs both in their inflammatory response and pathology. The pathology encountered in the 64 acute HAT infections is characterized by elevated Tumor necrosis factor alpha (TNF-α) while 65 that encountered in the chronic HAT infections is characterized by elevated transforming growth 66 factor (TGF-β) [8] . 67 Treatment of Trypanosoma brucei rhodesiense infections involves the use of early stage drugs 68 such as pentamidine and suramin [9] and late stage drugs such as melarsoprol; melarsoprol is the 69 only drug recommended by WHO for treatment of late-stage T b rhodesiense infection, but can 70 be lethal to 5% of patients owing to post-treatment reactive encephalopathy [10] . HAT therapy is 71 further complicated by reports of drug resistance in different foci, including against suramin and 72 melarsoprol in Tanzania [11] and against melarsoprol in south Sudan [12] . In their study, [13] 73 suggested that investigations into treatment failure in HAT and use of alternative drugs or 74 treatment regimens should not only focus on differential genotypes of the parasites but also on 75 differential virulence and tissue tropism as possible causes. The present study was therefore 4 76 designed to investigate the occurrence of differential virulence of isolates recovered from 77 Western Kenya/ Eastern Uganda HAT focus and the potential role of these variations on isolate 78 sensitivity to anti-trypanosomal drugs. The study will also avail well characterized 79 T.b.rhodesiense isolates for future studies. Experimental animals: 86 The study used 6-8 weeks old male Swiss White mice, each weighing 25-30 g live body weight. 87 The animals were obtained from the Animal Breeding Unit at KALRO-BioRI, Muguga. The 88 mice were housed in standard mouse cages and maintained on a diet consisting of commercial 89 pellets (Unga® Kenya Ltd). All experiments were performed according to the guidelines set by 90 the Institutional Animal Care and Use Committee (IACUC) of KALRO-BioRI. Briefly, water 91 was provided ad libitum. All mice were acclimatized for two weeks, during which time they 92 were screened and treated for ecto and endoparasites using ivermectin (Ivermectin®, Anupco, 93 Suffolk, England). During the two-week acclimation period, pre-infection data were collected on 94 body weights and packed cell volume once a week prior to parasite inoculation.
95

Trypanosomes and Cloning
96
Twelve T.b. rhodesiense trypanosome stabilates (KETRI 2482 (KETRI , 2487 were selected from the KALRO-BioRI specimen bank. 98 Cloning was carried out as described by [14] . Briefly, the trypanosome stabilates were inoculated 5 99 into mice immunosuppressed using cyclophosphamide at 100 mg/kg for three consecutive days 100 (total dose 300mg/kg) body weight (bwt) as previously described [15] . Animals were monitored 101 daily for parasitaemia. When the mice attained a parasitaemia score of 3.2.x10 7 102 trypanosomes/mL [16] , they were bled from the tail vein and the blood sample appropriately 103 diluted using a mixture of PSG pH 8.0 and guinea pig serum in the ratio of 1:1. Using the 104 hanging drop method [17], a single trypanosome was then picked using a syringe with a 25 105 gauge needle suspended in at least 0.2mls PSG pH 8.0 and injected intraperitoneally (ip) into a 106 single immunosuppressed mouse. This was replicated ten times to increase the chances of 107 success. Infected mice were then monitored for parasitaemia daily [16] . Any of the ten mice 108 which became parasitaemic was euthanized using concentrated carbon dioxide, bled from the 109 heart and the harvested trypanosomes cryopreserved in PSG pH 8.0 in 20% glycerol as a clone 110 stabilate.
111
Virulence studies 112 Design of virulence study 113 Male Swiss White mice were housed in groups of 10 in standard mouse cages containing wood 114 shavings as bedding material. The cryopreserved cloned parasites were thawed, and injected ip 115 into immunosuppressed donor Swiss White mice for multiplication. The mice were euthanized 116 using carbon dioxide[18] at peak parasitaemia and blood collected from the heart in EDTA for 117 quantification as previously described [19] .The ten mice in each cage were infected with one Tbr Blood for estimation of parasitaemia levels was collected daily for the first 14 days and 123 thereafter three times in a week from each mouse using the tail tip amputation method [20] . The 124 PP and parasitaemia progression were determined using the rapid matching method of [16] [21] . 125 The infected mice were monitored for 60 days post infection. (Table 2) in order to identify cut-off points for characterizing isolates as 7 145 drug resistant. Thereafter, the T. b. rhodesiense test clones were evaluated for sensitivity to the 146 same drugs (Table 3 ). An isolate was considered drug-resistant if 2/5 (40%) of the infected and 147 treated mice relapsed [11] after having been treated at 20mg/kg bwt. 148 Suramin and Pentamidine drugs (100% w/w) for the highest dosage of 40mg/kg bw was prepared 149 by dissolving 40mg of these drugs in 10mls distilled water to give a concentration of 4 mg/ml. 150 Diminazene aceturate ( 44.44% w/w active ingredient) for the highest dosage of 40mg/kg bw 151 was prepared by dissolving 90mg of the drug powder in 10mls distilled water to give a 152 concentration of 4mg/ml, whereas Melarsoprol (5 ml vials of 180 mg) was first prepared by 153 mixing (vortex) 1 Ml of the stock solution to 4 Ml of 50% propylene glycol to give a 154 concentration of 7.2mg/ml (72mg/kg).This was further diluted to 40mg/kg by mixing(vortex) 5.6 155 ml of the 7.2mg/ml with 4.4mls of 50% propylene glycol to give a concentration of 4mg/ml 156 (40mg/kg) The drug solutions for the 40mg/kg dose of each drug were then diluted serially using 157 distilled water to give dosages for the 20, 10, 5, 2.5, 2, 1mg/kg. (Table 1) . A total of 172 3/12 clones were very acute, 3/12 were acute, 2/12 sub-acute and 4/12 chronic (Table 1) . As 173 expected, the shortest mean± SE survival time of 8.7 ± 0.2 days was observed in mice infected 174 with the very-acute clones (Table 1) The mean ±SE pre-patent period in infected mice are summarized in (Table 1) as: very-acute Tbr 183 clones: 4.7±0.09 dpi, acute Tbr clones: 5.0±0.2 dpi, sub-acute Tbr clones: 5.2±0.08 dpi and 184 chronic Tbr clones: 6.3±0.2 dpi. Despite the apparent increasing trend of these data, these 185 differences were however not statistically significant (p> 0.05). Summary analysis on mean peak 186 parasitaemia (Mean ± SE) and number of days to peak parasitaemia (DPP) in each class are 187 presented in (Table 1) which remained largely constant throughout the duration of the study (Fig 3) . However, the onset 202 and severity of the anemia, as shown by the decline in PCV, was most prominent for mice 203 infected with the isolates classified as very acute (Fig3 reference sensitive isolate was sensitive to pentamidne at all doses above 4 mg/kg bwt (Table 2) . 230 It was also sensitive to all doses of suramin equal to or greater than 2.5 mg/kg ( Table 2) 231
The results of drug sensitivity experiments for the test Tbr clones are summarized in (Table 3) . 232 All the isolates recorded at least 80% cure rates to all the drug dose regimens evaluated in this 233 study (Table 3 ) and were therefore classified as sensitive. However, a few cases of relapses were 234 observed in 1/5 (20%) mice infected with KETRI 2482 (very-acute group) and treated with 235 diminazene aceturate at 2.5mg/kg, and KETRI 2487 (acute) and KETRI 3926 (sub-acute) treated 236 with pentamidine at 5mg/kg. In mice infected with KETRI 3928 (Chronic), 4/5 treated with 237 diminazene aceturate at 2.5mg/kg and 5/5 treated at 20 mg/kg died at 47 days post treatment due 238 to causes not related to trypanosome infection (Table 3) . No relapses were observed in mice 239 groups that were treated with either melarsoprol (1 and 20 mg/kg) or suramin at 2.5 mg/kg 240 (Table 3) 241 [24] . In our study, parasitaemia of isolates in the very-acute virulence class was represented by a 286 single wave whereas the acute, sub-acute and chronic virulence classes were represented by two 287 waves. (Fig 2) . This is in agreement with studies by [34] virulence class) and 3926 (sub-acute virulence class) were all against the two diamidines 328 (pentamidine or dimainazene) but not against suramin or melarsoprol (Table 3) which is 329 consistent with clinical practice of not using these specific diamidines to treat Tbr HAT (WHO, 330 2018). Overall, the fact that the test isolates were all sensitive (at least 80% cure rates) to the 331 drugs suggests there was no relationship between isolates' virulence and their sensitivity to anti-332 trypanosomal drugs.
333
The KALRO-BioRI reference isolate considered to be drug resistant was confirmed in this study 334 to be resistant to melarsoprol, pentamidine and diminazene aceturate ( Table 2 ). In general drug 335 resistance is attributed to reduced drug uptake due the mutation or absence of drug uptake gene 336 [41] as well as by enhanced drug export, mediated by a multidrug resistance-associated 337 protein, [42] . The uptake of the three drugs, melarsoprol, pentamidine and diminazene is 338 mediated by the P2 transporter [12, 43, 44] which explains why resistance to all three drugs is 339 linked. In contrast, uptake of suramin by trypanosomes is not mediated by the P2 transporter, 340 hence the reason why the trypanosome, KETRI 2538, retains sensitivity to suramin 341 In summary, this study has found that there exists variations in virulence of isolates recovered 342 from western Kenya/eastern Uganda HAT focus. Virulence is attributed to the production by the 343 blood stream forms of membranous nanotubes that originate from the flagellar membrane and 344 disassociate into free extracellular vehicles (EVs). This (EVs) contain several flagellar proteins 345 that contribute to virulence [45] . Our results are important as they have demonstrated that 346 virulence is not a hindrance in the control of trypanosomiasis by chemotherapy. However, our 347 study only tested the drug sensitivity at 24 hours post infection before trypanosomes could 348 establish themselves. There will be need to confirm our observation by administering the drugs 349 when animals are parasitaemic to ascertain the effectiveness of the drug in clearing the 350 established infections. 351 
